OrganaBio LLC has started construction on its current Good Manufacturing Practices (cGMP) manufacturing plant for cell and gene therapy manufacturing in Miami.
OrganaBio has partnered with Flad Architects and DPR Construction to design and build the facility.
The Miami-based GMP facility will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials.
Phase I of the facility is slated to open in the third quarter of 2021 and will include process development space, 1-2 ISO7 cleanrooms, a QC laboratory and support spaces.